Your medical briefing

Stay current.
Stay focused.

Research, guidelines, and safety alerts for your specialty.

All specialties Internal Medicine Family Medicine Pediatrics Cardiology Oncology Endocrinology Surgery

Emergency Medicine

Recent updates in Emergency Medicine from the last 30 days.

AllAll updates Research Guidelines Safety alerts

This multicenter randomized trial in China compared intravenous tenecteplase followed by endovascular thrombectomy (EVT) against EVT alone in 330 patients with moderate to severe basilar artery occlusion presenting 4.5 to 24 hours after stroke onset. The trial reported that functional independence at 90 days occurred in 30% of patients in both groups, with no significant difference, and symptomatic intracranial hemorrhage and 90-day mortality were similar between groups. The authors concluded that adding tenecteplase before EVT did not improve functional outcomes compared with EVT alone in this population.

Stay current.
Stay focused.

Emergency Medicine

Tenecteplase Before Thrombectomy Did Not Improve Late Basilar Stroke Outcomes

5-Year Surveillance Colonoscopy Noninferior to 3-Year After Adenoma Removal

Class I recall: Baxter Healthcare Corporation: Dextrose Injection, USP, 70 %, 2000 mL bags, Rx Only, Baxter Healthcare Corporat

CREST-2: Carotid Revascularization Does Not Improve Cognition

Short antibiotic course noninferior to long course in orthopedic infection

Azithromycin use rose, postpartum infections fell after trial evidence

Review outlines diagnosis and shunt outcomes in idiopathic NPH

Class I recall: OPTIMAL BALANCE PHARMACY: Glutathione 200 mg/mL, 30 mL sterile multidose vial, Each vial contains: Glutath

Class I recall: Baxter Healthcare Corporation: 0.9% Sodium Chloride Injection USP 500 mL, VIAFLEX Plastic Containers, with 24 u

Class II recall: Baxter Healthcare Corporation: Daptomycin, in 0.9% Sodium Chloride Injection, 1,000 mg per 100 mL (10 mg/mL), 1

Class II recall: Baxter Healthcare Corporation: Vasopressin, in 0.9% Sodium Chloride Injection, 20 units per 100 mL (0.2 units/m

Class II recall: Baxter Healthcare Corporation: Nexterone (amiodarone HCI), 360 mg/200 mL (1.8 mg/mL) in GALAXY Single-Dose Cont

Class II recall: Baxter Healthcare Corporation: Vasopressin, in 0.9% Sodium Chloride Injection, 40 units per 100 mL (0.4 units/m

Class II recall: ACCORD HEALTHCARE, INC.: Levothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 1000-count bottles, Rx Onl

Class II recall: ACCORD HEALTHCARE, INC.: Levothyroxine Sodium Tablets, USP, 125 mcg (0.125 mg), 1000-count bottles, Rx On

Class II recall: ACCORD HEALTHCARE, INC.: Levothyroxine Sodium Tablets, USP, 50 mcg (0.05 mg), 1000-count bottles, Rx Only

Class II recall: ACCORD HEALTHCARE, INC.: Levothyroxine Sodium Tablets, USP, 300 mcg (0.3 mg), 90-count bottles, Rx Only,

Class II recall: Mallinckrodt Hospital Products Inc.: Acthar Gel (repository corticotropin injection), 5 mL multiple-dose vial, Rx Onl

Class I recall: Fresenius Kabi USA, LLC: Tyenne (tocilizumab-aazg) Injection, 400 mg/20 mL (20 mg/mL), 20 mL vial, Rx Onl

Stay current. Stay focused.

Stay current.
Stay focused.